Time for a change: Addressing R&D and commercialization challenges for antibacterials

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 370, Issue 1670, 2015, Pages

  Payne, David J ^a   Miller, Linda Federici ^a   Findlay, David ^b   Anderson, James ^b   Marks, Lynn ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antibacterials; Challenges; Commercialization

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; DIAGNOSTIC PROCEDURE; DRUG DEVELOPMENT; ECONOMICS; HUMAN; INAPPROPRIATE PRESCRIBING; PHYSIOLOGY; POINT OF CARE SYSTEM; PROCEDURES; RESEARCH; SUPPLY AND DISTRIBUTION; TRENDS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; DRUG DISCOVERY; DRUG RESISTANCE, MICROBIAL; HUMANS; INAPPROPRIATE PRESCRIBING; POINT-OF-CARE SYSTEMS; RESEARCH;

EID: 84928653505     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2014.0086     Document Type: Article

References (29)

1. COMBACTE (Combating Bacterial Resistance in Europe). See http://www.combacte.com/About-us/ND4BB.
2. Rex JH. 2014 ND4BB: addressing the antimicrobial resistance crisis. Nat. Rev. Microbiol. 12, 231–232. (doi:10.1038/nrmicro3245)
3. Stavenger RA, Winterhalter M. 2014 TRANSLOCATION PROJECT: how to get good drugs into bad bugs. Sci. Transl. Med. 6, 228ed7. (doi:10.1126/scitranslmed.3008605)
4. DRIVE-AB. Driving reinvestment in R&D for antibiotics and advocating their responsible use. http://drive-ab.eu/ (accessed 12 March 2015).
5. Payne DJ. 2014 GlaxoSmithKline2140944: a novel bacterial topoisomerase inhibitor with activity against both conventional and biothreat pathogens, Abst. 143. Washington, DC: American Society of Microbiology Biodefense and Emerging Diseases.
6. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007 Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29–40. (doi:10.1038/nrd2201)
7. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. 2010 How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 9, 203–214. (doi:10.1038/nrd3078)
8. White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. 2004 Augmentin (amoxicillin/ clavulanate) in the treatment of communityacquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 53(Suppl. Si), 3–20. (doi:10.1093/jac/dkh050)
9. Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear J-C, Lameire NH. 2003 PK of atorvastatin and metabolites in healthy subjects. Nephrol. Dial. Transplant. 18, 967–976. (doi:10.1093/ndt/gfg048)
10. Bax BD et al. 2010 Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466, 935–940. (doi:10.1038/nature09197)
11. Page MGP. 2013 Siderophore conjugates. Ann. NY Acad. Sci. 1277, 115–126. (doi:10.1111/nyas.12024)
12. President’s Council of Advisors on Science and Technology (PCAST). Report to the President oncombating antibiotic resistance. http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf.
13. Mugabe C, Halwani M, Azghani AO, Lafrenie RM, Omri A. 2006 Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50, 2016–2022. (doi:10.1128/AAC.01547-05)
14. Shapiro AB, Jewman J, Goteti K, Beaudoin M, Harrison R, Hopkins S, Agrawal N, Rivin O. 2013 Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes. Antimicrob. Agents Chemother. 57, 4816–4824. (doi:10.1128/AAC.00163-13)
15. McEnaney PJ, Parker CG, Zhang AX, Spiegel DA. 2012 Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem. Biol 7, 1139–1151. (doi:10.1021/cb300119g)
16. Ghose C. 2013 Clostridium difficile infection in the twenty-first century. Emerg. Microb. Infect. 2, 62. (doi:10.1038/emi.2013.62)
17. Smith SB, Magid-Slav M, Brown JR. 2013 Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene expression data. PLoS ONE 8, 75607. (doi:10.1371/journal.pone.0075607)
18. Mellman I, Coukos G, Dranoff G. 2011 Cancer Immunotherapy comes of age. Nature 480, 480–489. (doi:10.1038/nature10673)
19. The White House. National Strategy for Combating Antibiotic Resistance, 2014. http://www.whitehouse.gov/sites/default/files/docs/carb_national_strategy.pdf.
20. European Medicines Agency. Telavancin (Vitabiv) EMEA/H/C/001240. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001240/human_med_001467.jsp&mid=WC0b01ac058001d124.
21. US Department of Health and Human Services, Food and Drug Administrations, Center for Drug Evaluation and Research. Guidance for industry: antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. Draft guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM359184.pdf.
22. European Medicines Agency. Addendum to the note for guidance on the evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95/ REV 2) to address indicationspecific clinical data. Draft, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129443.pdf.
23. Infectious Diseases Society of America (IDSA). Limited Population Antibacterial Drug (LPAD) approval mechanism. http://www.idsociety.org/uploadedFiles/IDSA/News_and_Publications/IDSA_News_Releases/2012/LPAD%20one%20pager.pdf.
24. H.R.3742 - Antibiotic Development to Advance Patient Treatment Act of 2013. 113th Congress (2013–2014). https://beta.congress.gov/bill/113thcongress/house-bill/3742.
25. Sertkaya A, Eyraud J, Birkenbach A, Franz C, Ackerley N, Overton V, Outterson K. 2014 Analytical framework for examining the value of antibacterial products. Washington, DC: US Department of Health and Human Services/ASPE.
26. Caliendo AM et al. 2013 Better tests, better care: improved diagnostics for infectious diseases. Clin. Infect. Dis. 57(3), 139–170. (doi:10.1093/cid/cit578)
27. Bhatt K, Kalia V, Berkowitz E, Twynholm M, Abraham-van Parijs B, Hodge R. 2005 Efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125mg (PKE AMX/CA) in patients with communityacquired pneumonia, including cases caused by penicillin-resistant S. pneumonia. 15th Eur. Congr. Clinical Microbiology and Infectious Diseases, Copenhagen, 2–5 April. Abstract 1134_02_88.
28. European Commission. First Horizon 2020 Work Programme update – launch of FTI and innovation prizes. http://europa.eu/rapid/press-release_MEMO-14-492_en.htm.
29. Monaco L, Holdren JP (The White House). New Executive actions to combat antibiotic resistance and protect public health: launch of a $20 million prize. http://www.whitehouse.gov/blog/2014/09/18/newexecutive-actions-combat-antibiotic-resistance-andprotect-public-health.